用于治疗癌症和免疫疾病的MALT1抑制剂
MALT1 Inhibitors for Treating Cancer and Immunological Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 West Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Aug 20;15(9):1419-1420. doi: 10.1021/acsmedchemlett.4c00390. eCollection 2024 Sep 12.
Abstract
Provided herein are novel MALT1 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer and immunological diseases and processes for preparing such compounds.
摘要
本文提供了新型MALT1抑制剂、药物组合物、此类化合物在治疗癌症和免疫疾病中的用途以及制备此类化合物的方法。
相似文献
1
MALT1 Inhibitors for Treating Cancer and Immunological Diseases.用于治疗癌症和免疫疾病的MALT1抑制剂
ACS Med Chem Lett. 2024 Aug 20;15(9):1419-1420. doi: 10.1021/acsmedchemlett.4c00390. eCollection 2024 Sep 12.
2
Novel MALT1 Inhibitors for Treating Cancer.用于治疗癌症的新型MALT1抑制剂
ACS Med Chem Lett. 2025 May 5;16(6):925-926. doi: 10.1021/acsmedchemlett.5c00229. eCollection 2025 Jun 12.
3
Novel TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.用于治疗自身免疫性和炎性疾病的新型酪氨酸激酶2（TYK2）抑制剂
ACS Med Chem Lett. 2024 Dec 9;16(1):8-9. doi: 10.1021/acsmedchemlett.4c00566. eCollection 2025 Jan 9.
4
Novel Phenylpiperidine Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer or Fibrotic Diseases.新型苯基哌啶衍生物作为QPCT和QPCTL抑制剂用于治疗癌症或纤维化疾病。
ACS Med Chem Lett. 2024 Oct 30;15(11):1826-1827. doi: 10.1021/acsmedchemlett.4c00495. eCollection 2024 Nov 14.
5
Novel Compounds as CDK2 Inhibitors for Treating Cancer.新型化合物作为治疗癌症的CDK2抑制剂
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
6
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.作为治疗心血管疾病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
7
Novel Piperidinylpyridinylcarbonitrile Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer.新型哌啶基吡啶基甲腈衍生物作为治疗癌症的QPCT和QPCTL抑制剂
ACS Med Chem Lett. 2025 Apr 14;16(5):758-759. doi: 10.1021/acsmedchemlett.5c00198. eCollection 2025 May 8.
8
Novel Piperidinylpyridinylcarbonitrile Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer.新型哌啶基吡啶基甲腈衍生物作为治疗癌症的QPCT和QPCTL抑制剂
ACS Med Chem Lett. 2025 Apr 2;16(4):540-541. doi: 10.1021/acsmedchemlett.5c00142. eCollection 2025 Apr 10.
9
Novel PARP7 Inhibitors for Treating Cancer.用于治疗癌症的新型聚（ADP-核糖）聚合酶7抑制剂
ACS Med Chem Lett. 2025 Mar 20;16(4):526-527. doi: 10.1021/acsmedchemlett.5c00127. eCollection 2025 Apr 10.
10
Pyrrolopyrazine Compounds as ERK5 Inhibitors for Treating Cancer.作为用于治疗癌症的细胞外信号调节激酶5（ERK5）抑制剂的吡咯并吡嗪化合物
ACS Med Chem Lett. 2024 Dec 11;16(1):16-17. doi: 10.1021/acsmedchemlett.4c00580. eCollection 2025 Jan 9.
引用本文的文献
1
Novel MALT1 Inhibitors for Treating Cancer.用于治疗癌症的新型MALT1抑制剂
ACS Med Chem Lett. 2025 May 5;16(6):925-926. doi: 10.1021/acsmedchemlett.5c00229. eCollection 2025 Jun 12.
本文引用的文献
1
Deciphering Regulatory T-Cell Dynamics in Cancer Immunotherapy: Mechanisms, Implications, and Therapeutic Innovations.解析癌症免疫治疗中的调节性T细胞动态：机制、意义及治疗创新
ACS Pharmacol Transl Sci. 2024 Jul 3;7(8):2215-2236. doi: 10.1021/acsptsci.4c00156. eCollection 2024 Aug 9.
2
Targeting the ubiquitin pathway in lymphoid malignancies.靶向淋巴恶性肿瘤的泛素途径。
Cancer Lett. 2024 Jul 10;594:216978. doi: 10.1016/j.canlet.2024.216978. Epub 2024 May 24.
3
The aryl hydrocarbon receptor-interacting protein in cancer and immunity: Beyond a chaperone protein for the dioxin receptor.癌症与免疫中的芳烃受体相互作用蛋白：超越二噁英受体的伴侣蛋白
J Biol Chem. 2024 Apr;300(4):107157. doi: 10.1016/j.jbc.2024.107157. Epub 2024 Mar 11.
4
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma.复发或难治性弥漫性大B细胞淋巴瘤基于免疫治疗的新策略进展
Exp Hematol Oncol. 2023 Aug 14;12(1):72. doi: 10.1186/s40164-023-00432-z.
Zotero 插件